Skip to main content
SpringerLink
Log in

Clinical Economics

A Method for Prospective Health Resource Data Collection

  • Original Research Article
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Summary

Information about the economic benefit of new drugs is becoming increasingly important for formulary considerations, reimbursement policies and related considerations. Although economic benefits of drugs have been analysed and reported, the economic benefits of drugs have rarely been examined in the course of randomised therapeutic trials. We designed a modular survey instrument, the Resource Utilisation Survey (RUS), to collect economic outcomes in prospective trials. A pilot test of the RUS was conducted using clinical trial methods in a study of nizatidine versus placebo in preventing ulcers induced by nonsteroidal anti-inflammatory drugs. The purpose of the pilot study was to evaluate the RUS instrument and corresponding study design issues in clinical trials for either acute or chronic diseases. With the lessons learned from the pilot study, the RUS has been used successfully in other ongoing clinical trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Bulpitt CJ, Fletcher AE. Economic assessments in randomized controlled trials. Medical Journal of Australia 153 (Suppl.): S16–S19, 1990

    PubMed  Google Scholar 

  • Crane VS. Developing a rational basis for cost-effective antibiotic selection in a community hospital: use of decision analysis method. Advances in Therapy 4: 137–144, 1987

    Google Scholar 

  • Crane VS. Economic aspects of clinical decision making: Applications of clinical decision analysis. American Journal of Hospital Pharmacy 45: 548–553, 1988

    PubMed  CAS  Google Scholar 

  • Dao TD. Cost-benefit and cost-effectiveness analysis of drug therapy. American Journal of Hospital Pharmacy 42: 791–802, 1985

    PubMed  CAS  Google Scholar 

  • Davies NE, Felder LH. Applying brakes to the runaway American health care system. Journal of the American Medical Association 263: 73–76, 1990

    Article  PubMed  CAS  Google Scholar 

  • Drummond MF. Principles of economic appraisal in health care. Oxford University Press, New York, 1980

    Google Scholar 

  • Drummond MF. Survey of cost-effectiveness and cost-benefit analyses in industrialised countries. World Health Statistics Quarterly 38: 383–401, 1985

    CAS  Google Scholar 

  • Drummond M, Davies L. Economic analysis alongside clinical trials. International Journal of Technology Assessment in Health Care 7: 561–573, 1991

    Article  PubMed  CAS  Google Scholar 

  • Drummond MF, Stoddart GL. Economic analysis and clinical trials. Controlled Trials 5: 115–128, 1984

    Article  CAS  Google Scholar 

  • Drummond MF, Stoddart GL, Torrance GW. Methods for the evaluation of health care programmes. Oxford Medical Publications, New York, 1987

    Google Scholar 

  • Drummond M, Teeling Smith G, Wells N. Economic evaluation in the development of medicines. Office of Health Economics, 1988

  • Eisenberg JM. New drugs and clinical economics: analysis of cost-effectiveness in the assessment of pharmaceutical innovations. Review of Infectious Diseases 6 (Suppl. 4): S905–S908, 1984

    Article  Google Scholar 

  • Eisenberg JM. Cost-benefit and cost-effectiveness analysis. In Cebul & Beck (Eds) Teaching clinical decision making, pp. 97–114, Praeger Publishers, New York, 1985

    Google Scholar 

  • Eisenberg JM. Clinical economics: a guide to the economic analysis of clinical practices. Journal of the American Medical Association 262: 2879–2886, 1989

    Article  PubMed  CAS  Google Scholar 

  • Eisenberg JM, Koffer H, Glick HA, Connell ML, Loss LE, et al. What is the cost of nephrotoxicity associated with aminoglycosides? Annals of Internal Medicine 107: 900–909, 1987

    PubMed  CAS  Google Scholar 

  • Finkler SA. The distinction between cost and charges. Annals of Internal Medicine 96: 102–109, 1982

    PubMed  CAS  Google Scholar 

  • Eisenberg JM, Koffer H, Glick HA, Connell ML, Loss LE, et al. What is the cost of nephrotoxicity associated with aminoglycosides? Annals of Internal Medicine 107: 900–909, 1987

    PubMed  CAS  Google Scholar 

  • Finkler SA. The distinction between cost and charges. Annals of Internal Medicine 96: 102–109, 1982

    PubMed  CAS  Google Scholar 

  • Henry D. Economic analysis as an aid to subsidisation decisions: the development of Australian guidelines for Pharmaceuticals. PharmacoEconomics 1: 54–67, 1992

    Article  PubMed  CAS  Google Scholar 

  • Hillman AL, Bloom BS. Economic effects of prophylactic use of misoprostol to prevent gastric ulcer in patients taking nonsteroidal anti-inflammatory drugs. Archives of Internal Medicine 149: 2061–2065, 1989

    Article  PubMed  CAS  Google Scholar 

  • Hillman AL, Eisenberg JM, Pauly MV, Bloom BS, Glick H, et al. Sounding board: avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies. New England Journal of Medicine 324: 1362–1365, 1991

    Article  PubMed  CAS  Google Scholar 

  • Hillman AL, Bloom BS. Economic effects of prophylactic use of misoprostol to prevent gastric ulcer in patients taking nonsteroidal anti-inflammatory drugs. Archives of Internal Medicine 149: 2061–2065, 1989

    Article  PubMed  CAS  Google Scholar 

  • Hillman AL, Eisenberg JM, Pauly MV, Bloom BS, Glick H, et al. Sounding board: avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies. New England Journal of Medicine 324: 1362–1365, 1991

    Article  PubMed  CAS  Google Scholar 

  • Hillman BJ, Kahan JP, Neu CR, Hammons GT. Clinical trials to evaluate cost-effectiveness. Investigative Radiology 24: 167–171, 1989

    Article  PubMed  CAS  Google Scholar 

  • Houts PS, Lipton A, Harvey HA, Martin B, Simmonds MA, et al. Nonmedical costs to patients and their families associated with outpatient chemotherapy. Cancer 53: 2388–2392, 1984

    Article  PubMed  CAS  Google Scholar 

  • Hurst JW. Reforming health care in seven European nations. Health Affairs, Millwood, 1991

    Google Scholar 

  • Johnson KF. Developing a cost base for pricing. Topics in Health Care Finances 14: 16–25, 1987a

    CAS  Google Scholar 

  • Johnson KF. Case study: procedure cost determination. Topics in Health Care Finances 14: 7–87, 1987b

    Google Scholar 

  • Leaf A. Sounding board: cost effectiveness as a criterion for Medicare coverage. New England Journal of Medicine 321: 898–900, 1989

    Article  PubMed  CAS  Google Scholar 

  • Simpson CA, Souney PF. Calculating costs of drug therapy: a review of a decade of literature (1977–1987). Clinical Therapeutics 10: 616–650, 1988

    PubMed  CAS  Google Scholar 

  • Strom BL. Pharmacoepidemiology, Churchill Livingstone, New York, 1989

    Google Scholar 

  • Warner KE, Luce BR. Cost-benefit and cost-effectiveness analysis in health care: principles, practice and potential. Health Administration Press, Ann Arbor, 1982

    Google Scholar 

  • Weinstein MC. Economic assessments of medical practices and technologies. Medical Decision Making 1: 309, 1981

    Article  PubMed  CAS  Google Scholar 

  • Wharton M, Cochi SL, Hutcheson RH, Bistowish JM, Schaffner W. A large outbreak of mumps in the postvaccine era. Journal of Infectious Diseases 158: 1253–1260, 1988

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Lilly Corporate Center, Eli Lilly and Company, Indianapolis, Indiana, USA

    Catherine Copley-Merriman, Lisa Egbuonu-Davis, James G. Kotsanos, Paul Conforti, Tim Franson, Gilad Gordon & Kati Copley-Merriman (Senior Clinical Research Administrator)

Authors
  1. Catherine Copley-Merriman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lisa Egbuonu-Davis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. James G. Kotsanos
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Paul Conforti
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tim Franson
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Gilad Gordon
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Kati Copley-Merriman
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Copley-Merriman, C., Egbuonu-Davis, L., Kotsanos, J.G. et al. Clinical Economics. Pharmacoeconomics 1, 370–376 (1992). https://doi.org/10.2165/00019053-199201050-00008

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-199201050-00008

Keywords

Search

Navigation